You are here: Home ยป Archives for NASDAQ

Telkomsel Expande Implantação da Capsyl Cloud com Synchronoss

BRIDGEWATER, N.J., March 03, 2026 (GLOBE NEWSWIRE) — A Synchronoss Technologies, Inc. (“Synchronoss” ou a “Empresa”), líder global e inovadora em plataformas de nuvem pessoal, anunciou hoje a expansão contínua da sua parceria com a Telkomsel, a principal operadora de rede móvel da Indonésia. Com base no sucesso do lançamento da Capsyl Cloud para assinantes móveis, a Telkomsel planeja estender o serviço a planos premium e benefícios pré-pagos para assinantes, com disponibilidade comercial prevista para 2026, reforçando a estratégia da operadora de oferecer uma experiência em nuvem liderada pela operadora e diferenciada das alternativas OTT (over-the-top).

Após a implantação inicial em março de 2025, o serviço continuou a se expandir em toda a base móvel da Telkomsel. Em junho de 2025, a Telkomsel lançou uma vantagem de armazenamento em nuvem de 50 GB como parte de determinados planos móveis, e introduziu um nível premium de 100 GB e 200 GB em setembro de 2025, viabilizando que os clientes armazenem, gerenciem e acessem com segurança suas fotos, vídeos e outros conteúdos digitais pessoais em todos os dispositivos.

A Telkomsel continuará a ampliar o serviço existente no primeiro trimestre de 2026, com a introdução de vantagens adicionais pré-pagas, ofertas agrupadas e aprimoramentos incrementais projetados para aumentar as opções do cliente e aprofundar o envolvimento em toda a sua base de assinantes móveis. Como parte do seu plano estratégico de longo prazo, a Telkomsel planeja estender o serviço a planos premium para todos os assinantes de telefonia móvel, com disponibilidade comercial prevista para 2026, oferecendo armazenamento seguro em nuvem e recursos de gerenciamento de conteúdo para todos os usuários de telefonia móvel da Telkomsel.

“A expansão contínua da Capsyl pela Telkomsel ressalta o papel crescente que os serviços de nuvem pessoal desempenham nas experiências móveis pós e pré-pagas”, disse Pat Doran, Diretor de Tecnologia e Vice-Presidente Executivo da Synchronoss. “Com a oferta de recursos de nuvem para dispositivos móveis pós-pagos e pré-pagos, a Telkomsel cria um ecossistema digital mais unificado para seus clientes, ao mesmo tempo em que abre novas oportunidades para impulsionar o engajamento e a fidelidade a longo prazo.”

“Com a crescente demanda de ferramentas digitais e o rápido crescimento do mercado de nuvem, a Telkomsel se preocupa em proporcionar aos clientes um estilo de vida digital com serviços em nuvem”, disse Lesley Simpson, Vice-Presidente de Estilo de Vida Digital da Telkomsel. “Com o sucesso do lançamento da Capsyl Cloud pela Telkomsel, os assinantes de planos pós-pagos da empresa podem continuar aprimorando o serviço enquanto se preparam para disponibilizá-lo a todos os usuários de planos premium. Agora, com uma experiência 5G aprimorada, essa evolução reflete nosso compromisso em fornecer soluções digitais seguras e práticas que se integram perfeitamente ao dia a dia.”

Capsyl Cloud é uma solução de nuvem pessoal segura e multiplataforma que permite aos usuários fazer backup, organizar e proteger fotos, vídeos e arquivos em smartphones, tablets e computadores. A plataforma é compatível com modelos de armazenamento em camadas, ofertas combinadas e atualizações premium, permitindo que os provedores de serviços personalizem os serviços em nuvem para diferentes segmentos de clientes.

Sobre a Telkomsel

A Telkomsel é a maior provedora de serviços de telecomunicações digitais da Indonésia, atendendo a centenas de milhões de clientes de telefonia móvel em todo o país. Como parte do Grupo Telkom, a Telkomsel oferece um amplo portfólio de serviços de conectividade, digitais e de estilo de vida, apoiando a transformação digital da Indonésia para consumidores, empresas e comunidades.

Sobre a Synchronoss

Synchronoss Technologies, líder global em soluções pessoais de nuvem, capacita os provedores de serviços a estabelecer conexões seguras e significativas com seus assinantes. Nossa plataforma SaaS Cloud simplifica os processos de integração e promove o envolvimento dos assinantes por meio do uso da inteligência artificial (IA), aprendizado de máquina e outros recursos avançados, resultando em fluxos de receita aprimorados, despesas reduzidas e tempo de comercialização mais rápido. Milhões de assinantes confiam na Synchronoss para proteger suas memórias mais queridas e conteúdo digital importante. Saiba como as nossas soluções focadas na Nuvem redefinem a forma da conexão digital com o seu mundo digital em www.synchronoss.com.

Contato de Relações com a Mídia:
Domenick Cilea
Springboard
[email protected]


GLOBENEWSWIRE (Distribution ID 9664687)

Telkomsel erweitert Capsyl Cloud-Bereitstellung mit Synchronoss

BRIDGEWATER, New Jersey, March 03, 2026 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. („Synchronoss“ oder das „Unternehmen“), ein weltweit führender Anbieter und Innovator im Bereich persönlicher Cloud-Plattformen, gab heute die weitere Ausweitung seiner Partnerschaft mit Telkomsel, Indonesiens führendem Mobilfunknetzbetreiber, bekannt. Nach der erfolgreichen Einführung von Capsyl Cloud für Mobilfunkkundinnen und -kunden plant Telkomsel, den Dienst auf Premium-Tarife sowie Prepaid-Vorteile auszuweiten. Die kommerzielle Verfügbarkeit ist für 2026 vorgesehen. Damit unterstreicht der Betreiber seine Strategie, ein netzbetreibergeführtes Cloud-Erlebnis anzubieten, das sich klar von Over-the-Top-Alternativen differenziert.

Nach dem Launch im März 2025 wurde der Service Schritt für Schritt auf die gesamte Mobilfunkbasis von Telkomsel ausgerollt. Im Juni 2025 integrierte Telkomsel im Rahmen ausgewählter Tarife 50 GB Cloud-Speicher als inkludierten Vorteil. Im September 2025 folgte die Einführung einer Premium-Stufe mit 100 GB und 200 GB. Damit können Kundinnen und Kunden ihre Fotos, Videos und anderen persönlichen digitalen Inhalte sicher speichern, organisieren und geräteübergreifend darauf zugreifen.

Im ersten Quartal 2026 wird Telkomsel auf dem bestehenden Service aufbauen und zusätzliche Prepaid-Vorteile, Paketangebote sowie schrittweise Verbesserungen einführen. Ziel ist es, die Auswahl für Mobilfunkkundinnen und -kunden zu erweitern und die Bindung zu vertiefen. Im Rahmen seiner längerfristigen Roadmap plant Telkomsel, Premium-Stufen für alle Mobilfunkkundinnen- und -kunden verfügbar zu machen. Die kommerzielle Einführung ist für 2026 vorgesehen, sodass alle Telkomsel Nutzerinnen und Nutzer sichere Cloud-Speicher- und Content-Management-Funktionen nutzen können.

„Die kontinuierliche Erweiterung von Capsyl durch Telkomsel zeigt, wie wichtig persönliche Cloud-Dienste mittlerweile sowohl für Postpaid- als auch für Prepaid-Erfahrungen sind“, erklärte Pat Doran, Chief Technology Officer und Executive Vice President von Synchronoss. „Mit der Ausweitung der Cloud-Funktionen auf beide Kundensegmente schafft Telkomsel ein einheitlicheres digitales Ökosystem und eröffnet gleichzeitig neue Chancen, Kundenbindung und langfristige Loyalität zu stärken.“

„Angesichts der steigenden Nachfrage nach digitalen Tools und des schnell wachsenden Cloud-Marktes möchte Telkomsel, dass seine Kundinnen und Kunden einen digitalen Lebensstil mit Cloud-Diensten genießen können“, so Lesley Simpson, Vice President of Digital Lifestyle bei Telkomsel. „Dank der erfolgreichen Einführung von Capsyl Cloud können unsere Postpaid-Kundinnen und Kunden den Service noch besser nutzen, während wir uns darauf vorbereiten, diesen Service allen Mobilfunknutzerinnen und -nutzern mit Premium-Tarifen anzubieten. In Kombination mit einem verbesserten 5G-Erlebnis unterstreicht diese Weiterentwicklung unser Engagement, sichere und praktische digitale Lösungen zu liefern, die sich nahtlos in den Alltag integrieren lassen.“

Capsyl Cloud ist eine sichere, plattformübergreifende persönliche Cloud-Lösung. Sie ermöglicht es Nutzerinnen und Nutzern, Fotos, Videos und Dateien auf Smartphones, Tablets und Computern zu sichern, zu organisieren und zu schützen. Die Plattform bietet gestaffelte Speicheroptionen, gebündelte Angebote und Premium-Upgrades, sodass Anbieter Cloud-Dienste gezielt auf unterschiedliche Kundensegmente zuschneiden können.

Über Telkomsel

Telkomsel ist Indonesiens größter Anbieter digitaler Telekommunikationsdienste und versorgt landesweit Hunderte Millionen Mobilfunkkundinnen und -kunden. Als Teil der Telkom Group bietet Telkomsel ein umfangreiches Portfolio an Konnektivitäts-, Digital- und Lifestyle-Diensten und treibt damit die digitale Transformation Indonesiens für Privatkundinnen und -kunden, Unternehmen und Gemeinschaften voran.

Über Synchronoss

Synchronoss Technologies, Inc. ist ein weltweit führender Anbieter persönlicher Cloud-Lösungen und unterstützt Dienstleister dabei, sichere und sinnvolle Verbindungen zu ihren Kundinnen und Kunden aufzubauen. Die SaaS-Cloud-Plattform von Synchronoss vereinfacht Onboarding-Prozesse und stärkt die Kundenbindung durch den Einsatz von Künstlicher Intelligenz (KI), maschinellem Lernen und weiteren fortschrittlichen Funktionen. So profitieren Anbieter von höheren Einnahmen, geringeren Kosten und schnelleren Markteinführungen. Millionen von Abonnentinnen und Abonnenten vertrauen darauf, dass Synchronoss ihre wertvollsten Erinnerungen und wichtigen digitalen Inhalte schützt. Erfahren Sie unter www.synchronoss.com, wie unsere Cloud-Lösungen die Art und Weise, wie Sie sich mit Ihrer digitalen Welt verbinden, neu definieren.

Medienkontakt:
Domenick Cilea
Springboard
[email protected]


GLOBENEWSWIRE (Distribution ID 9664687)

Telkomsel Expands Capsyl Cloud Deployment with Synchronoss

BRIDGEWATER, N.J., March 02, 2026 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”), a global leader and innovator in personal cloud platforms, today announced the continued expansion of its partnership with Telkomsel, Indonesia's leading mobile network operator. Building on the successful launch of Capsyl Cloud for mobile subscribers, Telkomsel plans to extend the service to premium tiers and prepaid perks for subscribers, with commercial availability targeted for 2026, reinforcing the operator’s strategy to deliver an operator-led cloud experience differentiated from over-the-top alternatives.

Following the initial deployment in March 2025, the service has continued to expand across Telkomsel’s mobile base. In June 2025, Telkomsel introduced a 50GB cloud storage perk as part of select mobile plans, followed by the introduction of a 100GB and 200GB premium tier in September 2025, enabling customers to securely store, manage, and access their photos, videos, and other personal digital content across devices.

Telkomsel will continue to build on the existing service in Q1 2026, introducing additional prepaid perks, bundled offers, and incremental enhancements designed to expand customer choice and deepen engagement across its mobile subscriber base. As part of its longer-term roadmap, Telkomsel plans to extend the service to premium tiers for all mobile subscribers with commercial availability targeted for 2026, bringing secure cloud storage and content management capabilities to all Telkomsel mobile users.

“Telkomsel’s continued expansion of Capsyl underscores the growing role personal cloud services play across both postpaid and prepaid mobile experiences,” said Pat Doran, Chief Technology Officer and Executive Vice President of Synchronoss. “By extending cloud capabilities across both postpaid and prepaid mobile, Telkomsel is creating a more unified digital ecosystem for its customers while unlocking new opportunities to drive engagement and long-term loyalty.”

“With the growing demand for digital tools and the fast-growing cloud market, Telkomsel cares for customers to have a digital lifestyle with cloud services,” said Lesley Simpson, Vice President of Digital Lifestyle at Telkomsel. “With Telkomsel's successful launch of Capsyl Cloud, Telkomsel's postpaid mobile subscribers can continue to enhance the service while preparing to bring these across all mobile users with premium tiers. Now, with a better 5G experience, this improved evolution reflects our commitment to delivering secure, practical digital solutions that fit seamlessly into everyday life.”

Capsyl Cloud is a secure, cross-platform personal cloud solution that enables users to back up, organize, and protect photos, videos, and files across smartphones, tablets, and computers. The platform supports tiered storage models, bundled offers, and premium upgrades, allowing service providers to tailor cloud services to different customer segments.

About Telkomsel

Telkomsel is Indonesia’s largest digital telecommunications service provider, serving hundreds of millions of mobile customers nationwide. As part of the Telkom Group, Telkomsel delivers a broad portfolio of connectivity, digital, and lifestyle services, supporting Indonesia’s digital transformation across consumers, enterprises, and communities.

About Synchronoss

Synchronoss Technologies, a global leader in personal Cloud solutions, empowers service providers to establish secure and meaningful connections with their subscribers. Our SaaS Cloud platform simplifies onboarding processes and fosters subscriber engagement using artificial intelligence (AI), machine learning, and other advanced features, resulting in enhanced revenue streams, reduced expenses, and faster time-to-market. Millions of subscribers trust Synchronoss to safeguard their most cherished memories and important digital content. Explore how our Cloud-focused solutions redefine the way you connect with your digital world at www.synchronoss.com.

Media Relations Contact:
Domenick Cilea
Springboard
[email protected]


GLOBENEWSWIRE (Distribution ID 9663824)

Zoom introduces next-gen Zoom Virtual Agent to automate end-to-end customer resolution

  • New virtual agent capabilities reduce customer effort, prevent repeat contacts, and give service leaders confidence to scale automation
  • With 43% of consumers saying chatbots fail to resolve their issues, Zoom Virtual Agent 3.0 can help organizations close that gap

SAN JOSE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) — Today Zoom Communications, Inc. (NASDAQ: ZM) unveiled Zoom Virtual Agent 3.0 (ZVA), the next evolution in agentic automation. ZVA introduces a new execution architecture and expanded AI capabilities designed to resolve customer issues end to end, seamlessly hand off to human agents, and help enterprises shift from transactional service interactions to connected customer relationships.

Organizations face growing pressure to automate more customer service interactions as volumes rise and cost efficiency becomes a priority. Enterprises are entering what Zoom calls the “resolution economy,” where competitive advantage is defined not by speed, but by first-contact resolution, reduced repeat contacts, and end-to-end workflow completion. Yet disjointed virtual agents can get stuck in silos, unable to seamlessly transfer full context to human agents, creating bottlenecks for complex issues. A recent Morning Consult report commissioned by Zoom found that the top three chatbot frustrations among the groups surveyed are failure to resolve the issue (43%), getting stuck in a loop (38%), and having to repeat information (37%).

“Agentic AI was just the beginning,” said Chris Morrissey, general manager of Zoom CX. “Zoom Virtual Agent 3.0 orchestrates multi-step workflows across systems, continuously learns from human resolutions, and provides full transparency into every agentic action. This allows organizations to confidently automate complex interactions. It’s more than a product update, it’s another step toward more connected customer relationships, where AI and humans work together to resolve issues faster and build trust.”

What's new in Zoom Virtual Agent 3.0

The next evolution of Zoom Virtual Agent operates across voice and chat, and introduces a new execution architecture designed to automate complex, cross-system interactions with enterprise governance. Unlike competing solutions focused primarily on conversational containment, ZVA is built for execution and resolution, securely orchestrating multi-step actions across systems with observability, control, and measurable outcomes. The following new features are now available:

  • Enhanced AI execution framework: Zoom Virtual Agent 3.0 is built on the latest Zoom AI Companion 3.0 architecture, allowing multi-step workflows to run across compatible CRM, billing, order management, and other enterprise systems with full observability and governance. This extends Zoom’s agentic AI capabilities by enabling full-cycle resolution rather than just single-step responses.
  • Agent journey transparency and governance enhancements: Account admins can now see the data sources, decision logic, and workflow paths behind automated actions. CX teams can audit performance, troubleshoot breakdowns, and refine automation policies, enabling responsible scaling without sacrificing adherence or control.

The following next-generation enhancements, expected to be generally available in Spring 2026, will expand ZVA’s ability to handle more complex workflows while improving reliability, oversight, and operational efficiency:

  • Multimodal large language model (LLM) intelligence: ZVA will be able to interpret and act on customer-submitted documents, images, and structured identifiers such as serial numbers and forms. By extracting relevant data directly from visual and document inputs, the virtual agent can automate service scenarios that previously required manual review, helping reduce customer effort and the need for escalation.
  • Continuous learning: When integrated with Zoom Contact Center, ZVA extracts insights from escalated engagements that human agents successfully resolved and applies those validated recommendations, with oversight and controls, to similar future requests. This creates a structured feedback loop based on human-agent resolutions, reducing repeat contacts and improving resolution consistency over time.
  • Proactive outbound engagement: The virtual agent can initiate contact, confirm updates, and complete tasks based on known events. This helps organizations resolve issues before customers reach out, reducing inbound volume and customer effort.

Zoom Virtual Agent in action

Modern customer issues rarely fit into a single scripted response. Zoom Virtual Agent (ZVA) is designed to move beyond basic automation, including authenticating users, interpreting inputs, orchestrating backend systems, and completing real business actions within a single, connected workflow.

By reducing repetitive steps and minimizing handoffs, ZVA helps increase first-contact resolution while lowering handling time and operational effort. An example of this is below:

  • Scenario: End-to-End Warranty Fulfillment
    • When a customer submits a warranty claim, ZVA can authenticate the user, extract a serial number from an uploaded image, validate eligibility across backend systems, schedule device pickup, initiate a replacement order, and confirm shipment, all within one continuous interaction.
    • If escalation is required, the complete workflow history, including verified inputs and actions already taken, transfers seamlessly to a live agent. The customer does not need to repeat information or restart the process, accelerating resolution and improving the overall experience.

Raising the bar for resolution

As organizations automate more interactions to manage rising volumes and cost pressures, performance is increasingly measured by resolution quality — not containment rates alone. In the resolution economy, automation must accurately interpret intent, execute across systems, and meaningfully reduce operational load.

Zoom is already seeing measurable results internally after implementing the latest updates to ZVA in its own virtual agents:

  • Query understanding accuracy: Zoom’s no-match rate (the percentage of total conversation turns in which a virtual agent failed to understand the user's input) has dropped from 35% to 0%, meaning almost all customer requests are accurately interpreted on the first attempt, reducing repeat queries and friction.
  • Significant time savings: On Zoom’s billing team, deflection rates (measuring the percentage of customer support inquiries resolved through self-service tools) rose from 0% to 30% in just three months, saving over 1,000 agent hours per month.

Zoom Virtual Agent 3.0 reflects Zoom’s broader ambition to power intelligent, connected customer experiences where AI and human agents work together to complete complex interactions with speed, transparency, and trust. This is automation designed not just to scale, but also to earn trust with every interaction.

See Zoom Virtual Agent in action

Read the Zoom blog to see how ZVA supports Zoom’s own customers by improving resolution at scale, and stop by Zoom’s booth (#519) at Enterprise Connect 2026, March 10–12 in Las Vegas, to see a live demo.

About Zoom

Zoom (NASDAQ:ZM) provides the AI-first, open work platform built for human connection and purposefully designed to move conversations to completion. From entrepreneurs to global enterprises, customers choose Zoom to seamlessly collaborate, communicate, and drive outcomes across meetings, chat, phone, contact center, events, and more — all with the built-in assistance of Zoom AI Companion. Founded in 2011, Zoom is headquartered in San Jose, CA. For more information, visit zoom.com.

Zoom Public Relations
Travis Isaman
[email protected]


GLOBENEWSWIRE (Distribution ID 9660155)

Nyxoah Annonce la Signature d'un Mémorandum d'Accord avec l'Hôpital Sheikh Shakhbout Medical City afin d'Améliorer la Prise en Charge du Traitement de l'AOS et d'Accélérer l'Accès à Genio au Moyen-Orient

Nyxoah Annonce la Signature d'un Mémorandum d'Accord avec l'Hôpital Sheikh Shakhbout Medical City afin d'Améliorer la Prise en Charge du Traitement de l'AOS et d'Accélérer l'Accès à Genio au Moyen-Orient

Mont-Saint-Guibert, Belgique – 18 février 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (« AOS ») par neuromodulation, a annoncé aujourd'hui la poursuite de ses efforts visant à renforcer sa présence au Moyen-Orient grâce à la signature d'un protocole d'accord avec Sheikh Shakhbout Medical City (SSMC), un hôpital phare des Émirats arabes unis spécialisé dans les soins complexes et graves, filiale de PureHealth, le plus grand groupe de soins de santé du Moyen-Orient. Ce protocole d'accord reflète l'orientation stratégique de Nyxoah, qui consiste à collaborer avec les centres médicaux régionaux d’excellence afin d'élargir l'accès à sa thérapie de stimulation du nerf hypoglosse (HGNS) Genio®, tout en soutenant les normes les plus élevées en matière de soins cliniques, d'éducation et de collaboration scientifique.

Dans le cadre de ce protocole d'accord, Nyxoah et SSMC s'engagent dans des initiatives visant à positionner SSMC comme un centre régional de premier plan pour la thérapie Genio. Ces efforts ont pour but de soutenir le développement d'un programme d'implantation à grand volume axé sur les soins centrés sur le patient.

Parallèlement, cette collaboration prévoit de faire du SSMC un centre régional de formation à la thérapie Genio au Moyen-Orient afin de soutenir la formation des chirurgiens, des médecins spécialistes du sommeil et des professionnels de santé référents de toute la région.

Nyxoah et le SSMC sont également engagés dans des discussions visant à explorer la recherche clinique et la collaboration dans le domaine de l'apnée du sommeil et de la prise en charge des maladies chroniques et métaboliques.

Olivier Taelman, Chief Executive Officer de Nyxoah, a commenté : “Compte tenu de la forte prévalence de l'apnée obstructive du sommeil au Moyen-Orient, cette initiative soutient notre vision d'offrir de nouvelles options de traitement aux patients de la région et d'explorer davantage l'impact de la prise en charge avancée de l'AOS sur les maladies chroniques et métaboliques telles que le diabète de type 2. Notre engagement actif auprès de Sheikh Shakhbout Medical City reflète notre stratégie de partenariat avec des institutions de premier plan afin de mettre en place des programmes cliniques durables, de soutenir la formation des médecins et de contribuer à l'amélioration des soins prodigués aux patients atteints d'apnée obstructive du sommeil.”

Dr. Marwan Al Kaabi, Chief Executive Officer de Sheikh Shakhbout Medical City, a ajouté : “À Sheikh Shakhbout Medical City, nous nous engageons à promouvoir des soins spécialisés et de haute qualité grâce à l'excellence clinique, à l'éducation et à la recherche. Notre collaboration avec Nyxoah soutient nos efforts visant à développer davantage notre expertise dans les thérapies innovantes contre l'apnée du sommeil et à servir de centre régional de référence pour la formation et les échanges scientifiques.”

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre-indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous-groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d’informations, visitez www.nyxoah.com

Attention – Marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

DÉCLARATIONS PROSPECTIVES
Certaines déclarations, convictions et opinions contenues dans ce communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le système Genio ; les études cliniques prévues et en cours sur le système Genio ; les avantages potentiels du système Genio ; les objectifs de Nyxoah en matière de développement, de parcours réglementaire et d'utilisation potentielle du système Genio ; la stratégie de commercialisation de la société et son entrée sur le marché américain ; et les résultats d'exploitation, la situation financière, la liquidité, les performances, les perspectives, la croissance et les stratégies de la société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent sensiblement de ceux exprimés ou sous-entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence défavorable sur les résultats et les effets financiers des plans et événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section « Facteurs de risque » du rapport annuel de la société sur le formulaire 20-F pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent considérablement de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant les tendances ou activités passées ne constituent pas des garanties de performances futures et ne doivent pas être interprétées comme une indication que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements futurs. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. Par conséquent, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, les conditions, les hypothèses ou les circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun des dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous-jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001165373)

Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East

Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East

Mont-Saint-Guibert, Belgium – February 18, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced continued progress in strengthening its presence in the Middle East through the signature of a Memorandum of Understanding (MoU) with Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the United Arab Emirates for serious and complex care and a subsidiary of PureHealth, the largest healthcare group in the Middle East. This MoU reflects Nyxoah’s strategic focus on working with leading regional medical centers to expand access to its Genio® hypoglossal nerve stimulation (HGNS) therapy, while supporting the highest standards of clinical care, education, and scientific collaboration.

As part of this MoU, Nyxoah and SSMC are engaged in initiatives aimed at positioning SSMC as a leading regional center for Genio therapy. These efforts are intended to support the development of a high-volume implant program with a strong focus on patient-centered care.

In parallel, the collaboration includes plans to establish SSMC as a regional training hub for Genio therapy in the Middle East to support the education of surgeons, sleep physicians, and referring healthcare professionals from across the region.

Nyxoah and SSMC are also engaged in discussions to explore clinical research and collaboration in the field of sleep apnea, chronic and metabolic disease management.

Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “Given the high prevalence of Obstructive Sleep Apnea in the Middle East, this initiative supports our vision to offer new treatment options to patients in the region and further explore the impact of advanced OSA management on chronic and metabolic diseases such as type 2 diabetes. Our active engagement with Sheikh Shakhbout Medical City reflects our strategy of partnering with leading institutions to build sustainable clinical programs, support physician education, and contribute to the advancement of care for patients living with obstructive sleep apnea.”

Dr. Marwan Al Kaabi, Chief Executive Officer of Sheikh Shakhbout Medical City, added: “At Sheikh Shakhbout Medical City, we are committed to advancing specialized, high-quality care through clinical excellence, education, and research. Our collaboration with Nyxoah supports our efforts to further develop expertise in innovative sleep apnea therapies and to serve as a regional reference center for training and scientific exchange.”

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Attachment


GLOBENEWSWIRE (Distribution ID 1001165373)

Fortrea erweitert Führungsteam und ernennt Oren Cohen zum Chief Medical Officer und Scott Dove zum President of Clinical Pharmacology Services

DURHAM, North Carolina, Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (das „Unternehmen“), eine weltweit führende Contract Research Organization (CRO), hat heute bekanntgegeben, dass es sein Führungsteam erweitert hat. Oren Cohen, MD, der zuvor sowohl als Chief Medical Officer (CMO) von Fortrea als auch als President of Clinical Pharmacology Services (CPS) tätig war, widmet sich nun ausschließlich seinen Aufgaben als CMO, nämlich der medizinischen Strategie, der wissenschaftlichen Leitung, der Ethik und der Governance-Aufsicht für das gesamte Fortrea-Portfolio. Scott Dove, PhD, ist der neue President of Clinical Pharmacology Services (CPS) bei Fortrea und verantwortlich für die frühen klinischen Entwicklungslösungen in Fortreas globalen Netzwerk von klinischen Forschungseinheiten. Cohen und Dove sind beide Mitglieder des Executive Committee von Fortrea.

„Die Aufnahme von Scott in das Fortrea-Team, während sich Oren nun voll und ganz den medizinischen und wissenschaftlichen Aspekten der Entwicklung widmet, ist ein Gewinn für unsere Kunden“, so Anshul Thakral, CEO. „Durch die enge Zusammenarbeit mit unseren Führungskräften in allen Phasen der klinischen Entwicklung wird Oren seine Beziehungen zu den Kunden vertiefen. Er beteiligt sich früher am wissenschaftlichen Dialog und arbeitet eng mit unseren Ärzten und therapeutischen Führungskräften zusammen, um komplexe Entwicklungsherausforderungen zu bewältigen und dabei die höchsten Standards der wissenschaftlichen Integrität und Patientensicherheit aufrechtzuerhalten. Scott hat sich schnell in unser Team für klinische Pharmakologie eingearbeitet und gewinnt derzeit einen direkten Einblick in unsere erstklassigen Kliniken. Er vereint einen starken technischen Hintergrund in der klinischen Entwicklung und im operativen Bereich mit einer erfolgreichen Führungsbilanz beim Aufbau und der Leitung globaler Organisationen. Ich freue mich auf seine Impulse zur weiteren Stärkung unseres Angebots.“

Oren Cohen, MD Chief Medical Officer

Oren Cohen, MD, ist ein erfahrener Experte in der Arzneimittelentwicklung und verfügt über mehr als 20 Jahre Erfahrung in verschiedenen leitenden medizinischen und wissenschaftlichen Funktionen der pharmazeutischen Industrie. Vor seiner Tätigkeit bei Fortrea war er als CMO und Head of Clinical Pharmacology Services bei Labcorp Drug Development tätig. Zuvor war er CMO bei Viamet Pharmaceuticals und hatte verschiedene leitende Positionen im medizinischen und operativen Bereich bei Quintiles inne, das heute zu IQVIA gehört.

Dr. Cohen erhielt seinen MD an der Duke University und absolvierte seine Facharztausbildung am New York Hospital, Cornell Medical Center, in New York City. Er absolvierte seine Schwerpunktweiterbildung (Fellowship) im Bereich Infektionskrankheiten am National Institute of Allergy and Infectious Diseases, wo er als Principal Investigator tätig war und als stellvertretender Direktor für medizinische Angelegenheiten des Instituts fungierte. Er ist Consulting Professor für Medizin am Duke University Medical Center, Mitglied des Board of Visitors der Duke University School of Medicine und Fellow der Infectious Diseases Society of America.

Scott Dove, PhD President Clinical Pharmacology Services

Scott Dove, PhD, bringt mehr als 25 Jahre Erfahrung in der Arzneimittelentwicklung zu Fortrea mit und war in verschiedenen Positionen mit zunehmender Verantwortung bei Pharma-, Biotech- und CRO-Unternehmen tätig. Zuletzt fungierte er als Berater für verschiedene Unternehmen, darunter auch Fortrea. Zuvor war Dr. Dove Chief Operating Officer bei Aravive, wo er die Forschungs- und Entwicklungsaktivitäten eines Onkologie-Biotech-Unternehmens in der klinischen Entwicklungsphase leitete. Darüber hinaus war er mehr als zehn Jahre lang in Führungspositionen bei PPD beschäftigt und war dort Leiter des Bereichs der frühen klinischen Entwicklung. Dr. Dove hatte außerdem Führungspositionen bei Allergan und Furiex Pharmaceuticals inne.

Dr. Dove promovierte am Texas A&M Health Science Center und erwarb seinen Bachelor of Science in Biochemie an der Texas A&M University.

Über Fortrea

Fortrea (Nasdaq: FTRE) ist ein weltweit führender Anbieter von Lösungen für die klinische Entwicklung in der Life-Sciences-Branche. Um Innovationen im Gesundheitswesen voranzutreiben und das Angebot lebensverändernder Therapien für Patienten zu beschleunigen, arbeiten wir mit aufstrebenden und großen biopharmazeutischen, biotechnologischen, medizintechnischen und diagnostischen Unternehmen zusammen. Fortrea bietet das Management von klinischen Studien der Phasen I–IV, klinische Pharmakologie sowie Beratungsdienste an. Die Lösungen von Fortrea basieren auf drei Jahrzehnten Erfahrung in mehr als 20 Therapiegebieten, einer Leidenschaft für wissenschaftliche Strenge, außergewöhnlichen Erkenntnissen und einem starken Netzwerk von Prüfzentren. Unser talentiertes und vielfältiges Team, das in etwa 100 Ländern tätig ist, ist darauf ausgelegt, Kunden weltweit fokussierte und flexible Lösungen zu bieten. Erfahren Sie mehr darüber, wie Fortrea zu einer transformativen Kraft von der Pipeline bis zum Patienten wird, unter Fortrea.com und folgen Sie uns auf LinkedIn und X (ehemals Twitter).

Fortrea-Ansprechpartner:
Tracy Krumme (Investoren) – 984-385-6707, [email protected]
Sue Zaranek (Medien) – 919-943-5422, [email protected]
Kate Dillon (Medien) – 646-818-9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9656033)

Fortrea Expande Equipe Executiva, Nomeia Oren Cohen como Diretor Médico e Scott Dove como Presidente dos Serviços de Farmacologia Clínica

DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (a “Empresa”), uma organização líder global de pesquisa por contrato (CRO), anunciou hoje a expansão da sua equipe executiva. Oren Cohen, MD, ex-diretor médico (CMO) da Fortrea e presidente dos Serviços de Farmacologia Clínica (CPS), agora se dedica à sua responsabilidade de CMO, ou seja, estratégia médica, liderança científica, ética e supervisão de governança em todo o portfólio da Fortrea. Scott Dove, PhD, junta-se à Fortrea como novo presidente de CPS, responsável pelas primeiras soluções de desenvolvimento clínico da Fortrea em toda a sua rede global de unidades de pesquisa clínica. Cohen e Dove atuam no Comitê Executivo da Fortrea.

“A entrada de Scott para a equipe da Fortrea e a dedicação total de Oren aos aspectos médicos e científicos do desenvolvimento, é uma vitória para os clientes”, disse Anshul Thakral, CEO. “Com seu trabalho em estreita colaboração com nossos líderes de negócios em todas as fases do desenvolvimento clínico, Oren irá aprofundar seu relacionamento com os clientes. Ele já está envolvido no diálogo científico e colaborando estreitamente com nossos médicos e líderes terapêuticos para ajudar a enfrentar desafios complexos de desenvolvimento, mantendo os mais altos padrões de integridade científica e segurança do paciente. Scott está se entrosando com a nossa equipe de Farmacologia Clínica e tendo uma visão em primeira mão de nossas clínicas de classe mundial. Ele tem uma sólida formação técnica em desenvolvimento clínico e operações e um histórico de sucessos na liderança da criação e liderança de organizações globais. Mal posso esperar por suas ideias sobre devemos fortalecer ainda mais nossa oferta.”

Oren Cohen, MD Diretor Médico

Oren Cohen, MD, é veterano do desenvolvimento de medicamentos, com mais de 20 anos de experiência em várias funções de liderança executiva médica e científica na indústria farmacêutica. Antes da Fortrea, o Dr. Cohen atuou como CMO e chefe dos Serviços de Farmacologia Clínica da Labcorp Drug Development. Anteriormente, foi CMO da Viamet Pharmaceuticals e atuou em vários cargos de liderança médica e operacional sênior na Quintiles, agora parte da IQVIA.

O Dr. Cohen é formado pela Duke University, fez seu estágio e residência no The New York Hospital, Cornell Medical Center, em Nova York. Ele completou sua bolsa em Doenças Infecciosas no Instituto Nacional de Alergia e Doenças Infecciosas, onde permaneceu como Investigador Principal e atuou como diretor assistente de assuntos médicos do instituto. Ele é Professor Consultor de Medicina do Duke University Medical Center, membro do Conselho de Visitantes da Duke University School of Medicine e Fellow da Infectious Diseases Society of America.

Scott Dove, PhD Presidente Serviços de Farmacologia Clínica

Scott Dove, PhD, traz mais de 25 anos de experiência em desenvolvimento de medicamentos para a Fortrea, tendo atuado em funções de responsabilidade crescente em empresas farmacêuticas, de biotecnologia e CRO. Recentemente, ele atuou como consultor de várias empresas, incluindo a Fortrea. Anteriormente, o Dr. Dove foi diretor de operações da Aravive, liderando as operações de P&D em um estágio clínico de biotecnologia focada em oncologia. Ele também atuou em cargos de liderança na PPD durante mais de uma década, onde liderou serviços de desenvolvimento inicial. O Dr. Dove também ocupou cargos de liderança na Allergan e na Furiex Pharmaceuticals.

O Dr. Dove recebeu seu PhD do Texas A&M Health Science Center e obteve seu bacharelado em bioquímica na Texas A&M University.

Sobre a Fortrea

A Fortrea (Nasdaq: FTRE) é fornecedora líder global de soluções para o desenvolvimento clínico para a indústria de ciências da vida. Fazemos parcerias com grandes e emergentes empresas biofarmacêuticas, de biotecnologia, de dispositivos médicos e de diagnóstico para impulsionar a inovação na saúde que acelera terapias que mudam a vida dos pacientes. A Fortrea fornece gerenciamento de testes clínicos de fase I-IV, farmacologia clínica e serviços de consultoria. As soluções da Fortrea utilizam suas três décadas de experiência abrangendo mais de 20 áreas terapêuticas, sua dedicação ao rigor científico, insights excepcionais e uma forte rede de pesquisadores. Nossa equipe talentosa e diversificada que trabalha em cerca de 100 países é dimensionada para fornecer soluções focadas e ágeis para clientes de todo o mundo. Saiba mais sobre como a Fortrea está se tornando uma força transformadora de pipeline para pacientes em Fortrea.com e siga-nos em LinkedIn e X (ex-Twitter).

Contatos da Fortrea:
Tracy Krumme (Investidores) – 984-385-6707, [email protected]
Sue Zaranek (Mídia) – 919-943-5422, [email protected]
Kate Dillon (Mídia) – 646-818-9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9656033)

Fortrea renforce son équipe de direction en nommant Oren Cohen au poste de directeur médical et Scott Dove à celui de président des services de pharmacologie clinique

DURHAM, Caroline du Nord, 17 févr. 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq : FTRE) (la « Société »), une organisation mondiale de recherche sous contrat (CRO) de premier plan, annonce ce jour l’élargissement de son équipe de direction. Oren Cohen, MD, qui occupait auparavant les fonctions de directeur médical (CMO) et de président des services de pharmacologie clinique (CPS) chez Fortrea, se consacre désormais à ses responsabilités de directeur médical, à savoir la stratégie médicale, le leadership scientifique, l’éthique et la supervision de la gouvernance à l’échelle de l’ensemble du portefeuille de Fortrea. Scott Dove, PhD, rejoint Fortrea en qualité de nouveau président des CPS. Il sera chargé de piloter les solutions de développement clinique précoce de l’entreprise au sein de son réseau mondial d’unités de recherche clinique. M. Cohen et M. Dove siègent tous deux au comité exécutif de Fortrea.

« L’arrivée de Scott au sein de l’équipe de Fortrea, tandis qu’Oren se consacre pleinement aux dimensions médicales et scientifiques du développement, constitue un atout majeur pour les clients », a déclaré Anshul Thakral, PDG. « En collaborant étroitement avec nos responsables commerciaux à chaque étape du développement clinique, Oren consolidera ses relations avec les clients. Il intervient plus en amont dans les échanges scientifiques et travaille en étroite collaboration avec nos médecins et responsables thérapeutiques afin de répondre aux défis complexes du développement, tout en veillant au respect des normes les plus strictes en matière d’intégrité scientifique et de sécurité des patients. Scott s’intègre rapidement à notre équipe de pharmacologie clinique et se familiarise de près avec nos cliniques de renommée internationale. Il associe une expertise technique approfondie en développement clinique et en opérations à une solide expérience de leadership dans la création et la gestion d’organisations internationales. Je me réjouis de pouvoir m’appuyer sur ses idées pour continuer à renforcer notre offre. »

Oren Cohen, MD, directeur médical

Le Dr Oren Cohen est un professionnel chevronné du développement de médicaments, fort de plus de 20 ans d’expérience dans des fonctions de direction médicale et scientifique au sein de l’industrie pharmaceutique. Avant de rejoindre Fortrea, le Dr Cohen a exercé les fonctions de directeur médical et de responsable des services de pharmacologie clinique chez Labcorp Drug Development. Auparavant, il a exercé en tant que directeur médical chez Viamet Pharmaceuticals et a occupé plusieurs postes de direction médicale et opérationnelle de haut niveau chez Quintiles, qui fait désormais partie d’IQVIA.

Le Dr Cohen est titulaire d’un doctorat en médecine de l’Université Duke et a effectué son internat et son résidanat au New York Hospital, Cornell Medical Center, à New York. Il a effectué son stage postdoctoral en maladies infectieuses à l’Institut national des allergies et des maladies infectieuses, où il est ensuite resté en qualité d’investigateur principal et a occupé le poste de directeur adjoint des affaires médicales de l’institut. Il est professeur consultant en médecine au Duke University Medical Center, membre du conseil d’administration de la faculté de médecine de l’université Duke et membre de l’Infectious Diseases Society of America.

Scott Dove, PhD, président des services de pharmacologie clinique

Scott Dove, PhD, rejoint Fortrea avec plus de 25 ans d’expérience dans le développement de médicaments, au cours desquels il a exercé des fonctions à responsabilités croissantes dans des entreprises pharmaceutiques, biotechnologiques et des CRO. Plus récemment, il a exercé en tant que conseiller pour plusieurs entreprises, y compris Fortrea. Auparavant, le Dr Dove a occupé le poste de directeur des opérations chez Aravive, où il supervisait les opérations de R&D d’une société de biotechnologie en phase clinique spécialisée en oncologie. Il a également exercé des fonctions de direction chez PPD pendant plus de dix ans, supervisant les services de développement clinique précoce. Le Dr Dove a par ailleurs exercé des fonctions de direction chez Allergan et Furiex Pharmaceuticals.

Le Dr Dove a obtenu son doctorat au Texas A&M Health Science Center et sa licence en biochimie à l’Université A&M du Texas.

À propos de Fortrea

Fortrea (Nasdaq : FTRE) est un fournisseur mondial de premier plan de solutions de développement clinique pour le secteur des sciences de la vie. Fortrea s’associe à des sociétés établies et émergentes du domaine biopharmaceutique, de la biotechnologie, des dispositifs médicaux et des diagnostics pour stimuler l’innovation en matière de santé, et accélérer la mise au point de traitements révolutionnaires pour les patients. Fortrea propose des services de gestion d’essais cliniques de phase I à IV, de pharmacologie clinique et de consulting. Nos solutions s’appuient sur 30 ans d’expérience dans 20 disciplines thérapeutiques, une passion pour la rigueur scientifique, des connaissances exceptionnelles et un solide réseau de centres de recherche. Notre équipe talentueuse et diversifiée, qui travaille dans près de 100 pays, est dimensionnée pour fournir des solutions ciblées et flexibles à nos clients, partout dans le monde. Pour en savoir plus sur la manière dont Fortrea est un moteur d’influence du pipeline au patient, rendez-vous sur Fortrea.com et suivez-nous sur LinkedIn et X (anciennement Twitter).

Contacts Fortrea :
Tracy Krumme (Investisseurs) – 984-385-6707, [email protected]
Sue Zaranek (Médias) – 919-943-5422, [email protected]
Kate Dillon (Médias) – 646-818-9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9656033)

JFB and XTEND Announce $1.5B Business Combination to Establish a Nasdaq-Listed US Leader in AI-Driven Autonomous Defense Robotics

  • Strategic investors in the merger include Eric Trump, Unusual Machines (NYSE: UMAC), American Ventures, LLC, Protego Ventures, Aliya Capital and Agostinelli Group.
  • Implied acquisition value of $1.5 billion, based on the price paid per share in concurrent private placement.
  • Merger to create an autonomous defense and security systems company combining AI-driven robotic operating system with established US operating and infrastructure capabilities, strengthening the security of the United States and its allied nations.

PALM BEACH, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) — JFB Construction Holdings (Nasdaq: JFB), a real estate development and construction company, announced today that it has entered into a definitive agreement to combine with XTEND, a software-first defense technology company anchored by its AI XTEND Operating System (XOS) in an all-stock transaction. The business combination is further supported by strategic investments from Eric Trump, Unusual Machines (NYSE: UMAC), American Ventures, LLC, Protego Ventures, and Aliya Capital. Following the closing of the business combination, the joint company is expected to be renamed XTEND AI Robotics and be listed on Nasdaq under the ticker “XTND.”

With headquarters and a production facility in Tampa, FL, the combined company expects to be well positioned to become a leading US provider of AI-driven autonomous defense and security solutions. XTEND delivers next-generation autonomous systems for defense, public safety, and private security applications built on its battle proven XOS operating system. XTEND’s products utilize remote operational capabilities, enabling multiple air, ground, and maritime drones to execute complex, dynamic missions with immediate operational readiness.

The transaction is also expected to support the expansion and increased NDAA-compliant, US-made domestic production capacity at XTEND’s Tampa, Florida production facility and ultimately accelerate the delivery of XTEND products to customers in the US, NATO allies, and Asia.

Aviv Shapira, Chief Executive Officer and Co-Founder of XTEND, commented:

“The demand for systems that keep operators out of harm’s way is surging as the global security environment grows more volatile, and this represents one of the largest market opportunities in defense technology today. By combining our platform with JFB, we are acquiring the resources we need to scale our manufacturing capabilities in the US and gaining access to the US public markets.”

Joseph F. Basile III, Chief Executive Officer of JFB, commented:

“What drew us to XTEND is the strength and scalability of its AI-driven operating system. XOS is not just a product, but a core autonomy platform that integrates software, hardware, and mission execution in real-world environments. By pairing XTEND’s operating system and advanced AI capabilities with JFB’s execution, infrastructure, and buildout expertise, we see a clear opportunity to accelerate US manufacturing, scale production responsibly, and support a next-generation defense technology platform built in America and ready for the public markets.”

Under the terms of the merger agreement, XTEND shareholders and JFB shareholders will receive shares of a new holding company, XTEND AI Robotics. Upon the closing of the transaction, current XTEND shareholders would own approximately 70.0% and JFB shareholders would own approximately 30.0% of XTEND AI Robotics’ fully diluted shares on a pro forma basis, not including shares reserved for issuances under XTEND AI Robotics’ equity incentive plans.

The merger has been unanimously approved by the board of directors of both companies and approved by written consent by JFB shareholders owning a majority of the outstanding common stock of JFB. The parties expect the transaction to close during the middle of 2026.

Advisors

Stifel is serving as exclusive financial advisor and a capital markets advisor to XTEND.

Paul Hastings LLP, H-F& Co, Banai Azriel Stern and Meitar Law Offices are serving as legal counsel to XTEND.

Dominari Securities LLC is serving as the exclusive placement agent to JFB Construction.

Sichenzia Ross Ference Carmel LLP and Amit Pollak Matlon are serving as legal counsel to JFB.

About JFB Construction Holdings

JFB Construction Holdings (“JFB”) offers generations of combined experience in residential and commercial construction and development. Having the experience of building multifamily communities, shopping centers, national franchises, exclusive estate & equestrian homes, and over 2 million square feet of commercial and retail. JFB provides hands-on, professional expertise, which has led to the quality and production we are known for.

JFB’s reputation has been built on its clients' trust and the value it brings to each project.

JFB is proud that most of its projects are obtained through referrals and repeat customers, and that to-date it has provided general contracting and construction management services in 36 US States.

About XTEND

XTEND is a software-first defense and security technology company building a unified operating ecosystem for human-guided autonomy across air, ground, and maritime domains. Anchored by its proprietary XOS operating system, XTEND’s products are designed to enable defense, public safety, and private security organizations to deploy, scale, and operate autonomous systems with immediate operational readiness in complex, high-risk environments. Founded in Tel Aviv, Israel, and headquartered in Tampa, Florida, the company combines battle-proven software with mission-optimized platforms, payloads, and manufacturing infrastructure to deliver integrated, NDAA-compliant solutions at scale. With more than 10,000 operational systems deployed across the world, XTEND is trusted worldwide where reliability, safety, and mission execution are critical. For more information, visit http://www.xtend.me.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

This communication contains, and oral statements made from time to time by our representatives may contain, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements regarding the potential transaction between XTEND Reality Expansion Ltd. (“XTEND”) and JFB Construction Holdings (“JFB”), including statements regarding the expected impacts and benefits of the potential transaction, timing of the transaction closing, and strategic initiatives for XTEND AI Robotics (“XTEND AI Robotics”) following the closing. All statements other than statements of historical facts contained in this communication may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “outlook”, “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this communication are only predictions. Xtend’s and JFB’s management have based these forward-looking statements largely on their current expectations and projections about future events and financial trends that management believes may affect its business, financial condition and results of operations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: the transaction may not be consummated; there may be difficulties with the integration and in realizing the expected benefits of the transaction; Xtend and JFB may need to use resources that are needed in other parts of its business to do so; there may be liabilities that are not known, probable or estimable at this time; the transaction may result in the diversion of management’s time and attention to issues relating to the transaction and integration; expected synergies and operating efficiencies attributable to the transaction may not be achieved within its expected time-frames or at all; there may be significant transaction costs and integration costs in connection with the transaction; the possibility that JFB will not have sufficient cash at close to satisfy the minimum cash condition; unfavorable outcome of legal proceedings that may be instituted against JFB and Xtend following the announcement of the transaction; risks inherent to the business may result in additional strategic and operational risks, which may impact Xtend’s, XTEND AI Robotics’ and JFB’s risk profiles, which each company may not be able to mitigate effectively; JFB’s ability to complete construction projects or other transactions on schedule and budget; changes in weather and occurrence of natural disasters and pandemics; recent imposition of tariffs by governments on construction materials, such as steel, aluminum and lumber; disruptions in supply chains; increase in the cost of labor and construction materials; JFB’s ability to maintain safe work sites; Xtend’s dependence on a limited number of defense and governmental security customers for a substantial portion of its business; significant delays or reductions in appropriations, Xtend’s programs and certain government fundings and programs more broadly, including as a result of a prolonged continuing resolution and/or government shutdown, and/or related to the global security environment or other global events; increased competition within JFB’s and Xtend’s markets and bid protests; changes in procurement and other U.S. and foreign laws, including changes through executive orders, contract terms and practices applicable to our industry, findings by certain applicable governments as to our compliance with such requirements, more aggressive enforcement of such requirements and changes in Xtend’s customers’ business practices globally; the improper conduct of employees, agents, subcontractors, suppliers, business partners or joint ventures in which Xtend participates, including the impact on Xtend’s reputation and its ability to do business; cyber and other security threats or disruptions faced by Xtend and JFB, its customers or its suppliers and other partners, and changes in related regulations; and Xtend’s ability to innovate, develop new products and technologies, progress and benefit from digital transformation and maintain technologies to meet the needs of Xtend’s customers. In addition, a number of important factors could cause JFB’s, Xtend’s or XTEND AI Robotics’ actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements, including but not limited to those important factors that will be discussed in the section entitled “Risk Factors” in the registration statement on Form S-4 to be filed by JFB and XTEND AI Robotics, as any such factors may be updated from time to time in other filings with the Securities and Exchange Commission (the “SEC”), including without limitation Xtend’s investor relations site at www.xtend.me and JFB’s investor relations site at https://investors.jfbconstruction.net/. Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, neither Xtend nor JFB undertakes any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Important Information for Investors and Stockholders

This communication is for informational purposes only and is not intended to, and does not, constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any issuance or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. In connection with the transaction, XTEND AI Robotics will file a registration statement on Form S-4, which will include an information statement of JFB, a proxy statement of XTEND and constitute a prospectus of XTEND AI Robotics. After the registration statement is declared effective, JFB will mail to its stockholders a definitive information statement that will form part of the registration statement. This communication is not a substitute for the information statement/proxy statement/prospectus or registration statement or for any other document that JFB or XTEND AI Robotics may file with the SEC and send to its stockholders in connection with the transaction. INVESTORS AND SECURITY HOLDERS OF XTEND AND JFB ARE URGED TO READ THE INFORMATION STATEMENT/PROXY STATEMENT/PROSPECTUS OR REGISTRATION STATEMENT AND ANY OTHER DOCUMENT THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the information statement/prospectus (when available) and other documents filed with the SEC by JFB through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by JFB will be available free of charge on JFB’s website at https://investors.jfbconstruction.net/.

JFB Construction Holdings Contact:

CORE IR
Mike Mason
516 222 2560
[email protected]

XTEND Contact:        
Headline Media
Sarah Small
929 255 1449
[email protected]

XTEND Investor Relations:
MZ North America
Shannon Devine
[email protected]
203-741-8811


GLOBENEWSWIRE (Distribution ID 9655605)